MX2019000271A - Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos. - Google Patents

Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.

Info

Publication number
MX2019000271A
MX2019000271A MX2019000271A MX2019000271A MX2019000271A MX 2019000271 A MX2019000271 A MX 2019000271A MX 2019000271 A MX2019000271 A MX 2019000271A MX 2019000271 A MX2019000271 A MX 2019000271A MX 2019000271 A MX2019000271 A MX 2019000271A
Authority
MX
Mexico
Prior art keywords
blood
brain barrier
humanized antibodies
transmigrating
antibodies
Prior art date
Application number
MX2019000271A
Other languages
English (en)
Inventor
Sulea Traian
Stanimirovic Danica
KEMMERICH Kristin
Durocher Yves
Original Assignee
Nat Res Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Council Canada filed Critical Nat Res Council Canada
Publication of MX2019000271A publication Critical patent/MX2019000271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de los mismos derivados por humanización de un anticuerpo existente, y a métodos para producirlos. Los anticuerpos humanizados de la presente invención muestran una unión potenciada al antígeno endotelial cerebral, una transmigración mejorada de un lado a otro de la barrera hematoencefálica, y una estabilidad térmica incrementada respecto al anticuerpo no humanizado de origen.
MX2019000271A 2016-07-06 2017-07-04 Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos. MX2019000271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662358777P 2016-07-06 2016-07-06
PCT/IB2017/054036 WO2018007950A1 (en) 2016-07-06 2017-07-04 Humanized antibodies transmigrating the blood-brain barrier and uses thereof

Publications (1)

Publication Number Publication Date
MX2019000271A true MX2019000271A (es) 2019-08-21

Family

ID=60912382

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000271A MX2019000271A (es) 2016-07-06 2017-07-04 Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.

Country Status (11)

Country Link
US (1) US10738115B2 (es)
EP (1) EP3481870A4 (es)
JP (1) JP7059494B2 (es)
KR (1) KR102406610B1 (es)
CN (1) CN109641970B (es)
AU (1) AU2017293450A1 (es)
BR (1) BR112019000220A2 (es)
CA (1) CA3029136A1 (es)
IL (1) IL263937A (es)
MX (1) MX2019000271A (es)
WO (1) WO2018007950A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109663A1 (en) 2016-12-12 2018-06-21 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
AU2018212860A1 (en) * 2017-01-30 2019-08-15 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
WO2019204912A1 (en) * 2018-04-24 2019-10-31 National Research Council Of Canada Blood-brain barrier transmigrating therapeutic compounds and uses thereof
EP3794036A4 (en) * 2018-05-18 2022-07-27 National Research Council of Canada ANTIBODIES AND ANTIBODY FRAGMENTS AGAINST THE HNAV1.7 CHANNEL AND THEIR USE IN INDICATIONS OF PAIN AND CANCER
JP2022509372A (ja) * 2018-10-29 2022-01-20 バイオジェン・エムエイ・インコーポレイテッド 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント
JP2022528459A (ja) * 2019-04-05 2022-06-10 ビー － ポータル バイオロジクス、インコーポレイテッド 融合構築物及びその使用
CN113874078A (zh) 2019-04-05 2021-12-31 Tauc3生物制品有限公司 抗tauc3抗体及其应用
KR20220133944A (ko) * 2020-01-28 2022-10-05 위스콘신 얼럼나이 리서어치 화운데이션 인간 혈액-뇌 장벽 표적화 항체
CN111635457A (zh) * 2020-05-22 2020-09-08 上海药明生物医药有限公司 一种纳米抗体人源化的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711303B2 (en) 1993-07-30 2009-06-10 Affymax, Inc. Biotinylation of proteins
JP2000014383A (ja) * 1998-07-03 2000-01-18 Igaku Seibutsugaku Kenkyusho:Kk ヒト化抗体
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2003046560A2 (en) 2001-11-30 2003-06-05 National Research Council Of Canada Self-assembly molecules
EP1452601A1 (en) 2003-02-28 2004-09-01 Roche Diagnostics GmbH Enhanced expression of fusion polypeptides with a biotinylation tag
CA2623841C (en) 2005-09-27 2019-03-12 National Research Council Of Canada Methods of identifying agents capable of tmem30a mediated transmigration across the blood brain barrier (bbb)
CA2653444A1 (en) * 2006-06-07 2007-12-13 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
WO2011127580A1 (en) 2010-04-14 2011-10-20 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
JP6093715B2 (ja) * 2011-01-28 2017-03-08 ナショナル リサーチ カウンシル オブ カナダ 免疫グロブリンドメインの工学的作製
NZ626620A (en) * 2012-01-10 2016-07-29 Biogen Ma Inc Enhancement of transport of therapeutic molecules across the blood brain barrier
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
KR102355309B1 (ko) * 2014-03-06 2022-01-24 내셔날 리서치 카운실 오브 캐나다 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
HRP20231514T1 (hr) * 2014-03-26 2024-03-01 Julius-Maximilians-Universität Würzburg Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka

Also Published As

Publication number Publication date
JP7059494B2 (ja) 2022-04-26
CA3029136A1 (en) 2018-01-11
IL263937A (en) 2019-01-31
BR112019000220A2 (pt) 2019-04-24
EP3481870A1 (en) 2019-05-15
AU2017293450A1 (en) 2019-02-14
CN109641970B (zh) 2022-11-18
KR20190025954A (ko) 2019-03-12
US10738115B2 (en) 2020-08-11
CN109641970A (zh) 2019-04-16
JP2019525743A (ja) 2019-09-12
US20190241653A1 (en) 2019-08-08
WO2018007950A1 (en) 2018-01-11
EP3481870A4 (en) 2020-03-11
KR102406610B1 (ko) 2022-06-08

Similar Documents

Publication Publication Date Title
MX2019000271A (es) Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
NZ736728A (en) Cd123 antibodies and conjugates thereof
MX2022002364A (es) Anticuerpos anti-pd-l1.
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
PH12017500890A1 (en) Antibody drug conjugates
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
MY195993A (en) Antibodies and Antibody Fragments for Site-Specific Conjugation
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
NZ728688A (en) Anti-pd-1 antibodies
MX2016009050A (es) Construcciones biespecificas de union a los antigenos cd3 y cd19.
EP3702372A3 (en) Anti-cd40 human antibodies
PH12016501366A1 (en) Novel anti-baff antibodies
EP3294766C0 (en) HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3
EA201792055A1 (ru) Антитела против cd48 и их конъюгаты
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
MX2023006416A (es) Anticuerpos, usos y metodos.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
PH12019502298A1 (en) Monoclonal antibody to pd-l1
WO2013115410A3 (en) Anti-phospholipase d4 antibody
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
EP3336172A4 (en) Method for producing antigen specific monoclonal antibody
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra